FWIW, this is a pic of my product revenue table. Yellow highlights are still estimates. Notably, Onpattro patients are starting to move to Amvuttra. Leqvio is still just my guess on the numbers, but NVS reported $34M in sales, so that's about 10,000 patients. Givlaari was basically flat Q/Q. No guarantees on the numbers, but I tried.